Actively Recruiting
Defining Inflammatory Biomarkers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
Led by University of Vermont · Updated on 2026-02-03
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating why people with myelodysplastic syndromes (MDS), a type of blood cancer, have a higher risk of heart problems such as heart disease and stroke. The study aims to understand if certain inflammation-related proteins in the blood can help predict these cardiovascular issues in patients with MDS. By gaining better insight, the research hopes to improve ways to detect and manage heart disease risks in these patients. This observational study will follow adults with MDS over a period of 6 months. Participants will attend an initial hospital visit to learn about the study, provide consent, share health information, and give a fasting blood sample. Following this, participants will return weekly for 3 weeks to provide more fasting blood samples. Then, they will have monthly visits for the next 5 months to discuss health changes and provide additional blood samples. All blood collections will occur during routine clinical care visits and take about 20 minutes each. During the study, researchers will collect small amounts of blood at each visit to measure markers of inflammation. Participants will receive reminder calls before blood draws. No treatments are given as part of this study; instead, the focus is on monitoring blood markers and health changes. The main outcome is to observe the natural variability of inflammation markers over 6 months. Participation helps researchers learn about inflammation's role in heart health for people with MDS.
CONDITIONS
Brief Title
Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Histologically confirmed diagnosis of myelodysplastic syndromes by bone marrow biopsy morphology using the 2022 WHO classification
- Eastern Cooperative Oncology Group (ECOG) performance status of 3 or less
- Expected survival of at least 6 months
- Ability to provide consent
You will not qualify if you...
- Initial diagnosis of MDS with excess blasts 2 according to 2022 WHO criteria
- Expected hematopoietic stem cell transplantation within 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants who undergo routine care are observed. Blood samples are collected at regular appointments as part of standard care to study inflammation markers.
Weekly visits for 3 weeks, then monthly visits for 5 months
Trial Site Locations
Total: 1 location
1
University of Vermont
Burlington, Vermont, United States, 05495-2038
Actively Recruiting
Research Team
D
Diego Adrianzen Herrera, MD
N
Neil A Zakai, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here